Literature DB >> 10735919

Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis.

F Carbonnel1, D Gargouri, M Lémann, L Beaugerie, S Cattan, J Cosnes, J P Gendre.   

Abstract

BACKGROUND: Intensive intravenous treatment remains the first line therapy of severe, uncomplicated attacks of ulcerative colitis. AIM: To predict the failure of intensive intravenous treatment by combining clinical and laboratory parameters with endoscopy findings.
METHODS: Retrospective study conducted in a tertiary care referral centre. Failure of intensive intravenous treatment was defined as colectomy before day 30, intravenous cyclosporin, or death. Predictive factors of outcome were assessed using univariate and multivariate prognostic analysis.
RESULTS: Between January 1990 and May 1997, 85 consecutive patients were treated with intensive intravenous treatment for non-response to oral corticosteroids (n=59) and/or severe attack of ulcerative colitis (n=26). There were 41 successes and 44 failures (including 1 death, 13 cyclosporin and 30 colectomies before day 30). Multivariate prognostic analysis found that the presence of Truelove and Witts' criteria (P=0.018), an attack that had lasted more than 6 weeks (P=0.001), and severe endoscopic lesions (P=0.007) were associated with an increased risk of failure. Patients with severe endoscopic lesions and Truelove and Witts' criteria, or an attack of more than 6 weeks had a failure rate of 85-86%.
CONCLUSION: Clinical, laboratory and endoscopic findings can predict the risk of failure of intensive intravenous treatment. A prospective study is required to confirm these results.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10735919     DOI: 10.1046/j.1365-2036.2000.00705.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  24 in total

Review 1.  Role of endoscopy in predicting the disease course in inflammatory bowel disease.

Authors:  Matthieu Allez; Marc Lémann
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

Review 2.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

3.  Fulminant colitis.

Authors:  Bruce E Sands
Journal:  J Gastrointest Surg       Date:  2008-09-03       Impact factor: 3.452

Review 4.  Clinical implications of mucosal healing for the management of IBD.

Authors:  Guillaume Pineton de Chambrun; Laurent Peyrin-Biroulet; Marc Lémann; Jean-Frédéric Colombel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-12-01       Impact factor: 46.802

5.  Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis.

Authors:  Han Ho Jeon; Hyun Jung Lee; Hui Won Jang; Jin Young Yoon; Yoon Suk Jung; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

Review 6.  The use of prognostic factors in inflammatory bowel diseases.

Authors:  Thomas Billiet; Marc Ferrante; Gert Van Assche
Journal:  Curr Gastroenterol Rep       Date:  2014-11

Review 7.  Autologous bone marrow stem cell transplantation for the treatment of ulcerative colitis complicated with herpes zoster: a case report.

Authors:  Hang Xiang; Xiaomei Zhang; Chao Yang; Wenhuan Xu; Xin Ge; Rong Zhang; Ya Qiu; Wanjun Sun; Fan Li; Tianyuan Xiang; Haixu Chen; Zheng Wang; Qiang Zeng
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

Review 8.  Evolving medical therapies for ulcerative colitis.

Authors:  P Y Chung; R D Cohen
Journal:  Curr Gastroenterol Rep       Date:  2001-12

9.  Management of acute colitis and toxic megacolon.

Authors:  Scott A Strong
Journal:  Clin Colon Rectal Surg       Date:  2010-12

10.  Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors.

Authors:  Shigeki Bamba; Akira Andoh; Hirotsugu Imaeda; Hiromitsu Ban; Ayako Kobori; Yousuke Mochizuki; Makoto Shioya; Takashi Nishimura; Osamu Inatomi; Masaya Sasaki; Yasuharu Saitoh; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  Exp Ther Med       Date:  2012-04-11       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.